All In Biotech

Drug Trial Radar · NCT07903493

Phase Ia Study of MST-931 in Healthy Adult Subjects

A Phase Ia, Randomized, Double-blind, Placebo-controlled, Single Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MST-931 in Healthy Adult Subjects

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

Jul 30, 2027

Study completion Jul 30, 2027

Sponsor

Sponsor type
Industry
Collaborators
Mabsoft Therapeutics (Australia) Pty. Ltd.; Mabsoft Therapeutics (Guangdong Hengqin) Co., Ltd.
First posted
Oct 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Phase 1a, randomized, double-blind study of MST-931 in healthy participants. The purpose of this research is to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single subcutaneous dose of MST-931 given to healthy participants. MST-931 is a monoclonal antibody.

Conditions

  • Ankylosing Spondylitis (AS)

Interventions

  • MST-931Biological

    MST-931 is a proprietary monoclonal antibody developed by Mabsoft Therapeutics.

  • MST-931 PlaceboBiological

    Matching placebo for MST-931

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of subjects with drug related adverse events (AEs)Time frame: Through study completion, up to 113 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Q-Pharm Pty Ltd

    Herston, Queensland, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.